Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 17718
Country/Region: Kenya
Year: 2017
Main Partner: IMA World Health
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: USAID
Total Funding: $8,475,481 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Pediatric Care and Support (PDCS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $336,096
Testing: HIV Testing and Counseling (HVCT) $689,044
Sexual Prevention: Other Sexual Prevention (HVOP) $1,704,766
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $952,595
Treatment: Adult Treatment (HTXS) $4,594,740
Treatment: Pediatric Treatment (PDTX) $198,240
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 38
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 35
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 33
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2018 4
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 564
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 106
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 532
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 59
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 752
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 176
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 665
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 74
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 865
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 202
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 765
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 85
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 1,354
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 317
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 1,197
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 129
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2018 188
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2018 44
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2018 133
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2018 18
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 188
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 7,088
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 1,250
GEND_GBV Number of people receiving post-GBV care 2018 8,338
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 288,361
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2018 5
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 2,923
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 18,687
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 44,235
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2018 32
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2018 50
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2018 315
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2018 68
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2018 63
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2018 113
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2018 191
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2018 414
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2018 294
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative 2018 656
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative 2018 412
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2018 98
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2018 51
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 2,359
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 866
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 974
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 2,387
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 3,063
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 7,816
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 3,805
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 13,931
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 10,995
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 803
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 1,281
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 684
HTS_TST Service Delivery Point (Facility) TB: <1, Negative 2018 18
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2018 36
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2018 18
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2018 18
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 60
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 90
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 114
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 156
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 1,332
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 2,075
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2018 109
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 66
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2018 1,052
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 4,729
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 2,764
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 2,169
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 8,004
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 3,648
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 26,438
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 15,493
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 48,022
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 27,479
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2018 4,415
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2018 3,510
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2018 3,471
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2018 672
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2018 1,035
HTS_TST Service Delivery Point (Facility) VMMC: 25-49, Negative 2018 1,046
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2018 193
HTS_TST Sum of Test Result disaggregates 2018 12,573
HTS_TST_POS By Test Result: Positive 2018 12,573
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 19
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 191
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 731
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2018 13
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2018 13
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2018 36
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive 2018 63
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 25
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 21
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 59
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 319
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 106
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 1,087
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 586
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 82
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 86
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2018 35
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2018 12
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2018 18
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2018 30
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2018 12
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 462
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 522
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2018 18
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2018 24
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2018 89
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2018 72
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2018 44
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 155
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 64
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 1,458
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 476
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 3,369
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 1,719
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2018 195
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2018 307
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 187
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 3,543
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 3,730
PMTCT_ART Already on ART at beginning of current pregnancy 2018 2,370
PMTCT_ART New on ART 2018 808
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 3,178
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 69,221
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 3,178
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 1,298
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 75
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 1,708
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 97
PMTCT_STAT By Age (Numerator): 10-14 2018 5
PMTCT_STAT By Age (Numerator): 15-19 2018 2,950
PMTCT_STAT By Age (Numerator): 20-24 2018 19,206
PMTCT_STAT By Age (Numerator): 25-49 2018 47,028
PMTCT_STAT By Age (Numerator): 50+ 2018 32
PMTCT_STAT By Number of known positives: 15-19 2018 7
PMTCT_STAT By Number of known positives: 20-24 2018 324
PMTCT_STAT By Number of known positives: 25-49 2018 2,068
PMTCT_STAT By Number of new negative: 10-14 2018 5
PMTCT_STAT By Number of new negative: 15-19 2018 2,923
PMTCT_STAT By Number of new negative: 20-24 2018 18,687
PMTCT_STAT By Number of new negative: 25-49 2018 44,229
PMTCT_STAT By Number of new negative: 50+ 2018 32
PMTCT_STAT By Number of new positives: 15-19 2018 19
PMTCT_STAT By Number of new positives: 20-24 2018 194
PMTCT_STAT By Number of new positives: 25-49 2018 733
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 69,221
PMTCT_STAT_den By Age (Denominator): <15-19 2018 3,059
PMTCT_STAT_den By Age (Denominator): 10-14 2018 5
PMTCT_STAT_den By Age (Denominator): 20-24 2018 20,553
PMTCT_STAT_den By Age (Denominator): 25-49 2018 45,572
PMTCT_STAT_den By Age (Denominator): 50+ 2018 32
PP_PREV Age/sex: 10-14 Female 2018 7,038
PP_PREV Age/sex: 10-14 Male 2018 310
PP_PREV Age/sex: 15-19 Female 2018 6,326
PP_PREV Age/sex: 15-19 Male 2018 702
PP_PREV Age/sex: 20-24 Female 2018 2,791
PP_PREV Age/sex: 20-24 Male 2018 784
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 17,951
PP_PREV Sum of Age/Sex disaggregates 2018 17,951
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 50
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 689
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 54
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 782
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 1,575
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 1,575
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 50
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 689
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 54
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 782
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 51
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 2,147
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 57
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 2,947
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 5,202
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 5,456
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 53
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 2,255
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 61
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 3,087
TX_CURR Age/Sex: <1 2018 172
TX_CURR Age/Sex: <1-9 2018 653
TX_CURR Age/Sex: 10-14 Female 2018 487
TX_CURR Age/Sex: 10-14 Male 2018 441
TX_CURR Age/Sex: 15-19 Female 2018 758
TX_CURR Age/Sex: 15-19 Male 2018 464
TX_CURR Age/Sex: 20-24 Female 2018 3,411
TX_CURR Age/Sex: 20-24 Male 2018 1,005
TX_CURR Age/Sex: 25-49 Female 2018 20,351
TX_CURR Age/Sex: 25-49 Male 2018 9,469
TX_CURR Age/Sex: 50+ Female 2018 2,284
TX_CURR Age/Sex: 50+ Male 2018 2,136
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 41,631
TX_CURR Sum of age/sex disaggregates 2018 1,222
TX_NEW By Age/Sex: <1 2018 105
TX_NEW By Age/Sex: 1-9 2018 97
TX_NEW By Age/Sex: 10-14 Female 2018 42
TX_NEW By Age/Sex: 10-14 Male 2018 35
TX_NEW By Age/Sex: 15-19 Female 2018 151
TX_NEW By Age/Sex: 15-19 Male 2018 48
TX_NEW By Age/Sex: 20-24 Female 2018 1,187
TX_NEW By Age/Sex: 20-24 Male 2018 271
TX_NEW By Age/Sex: 25-49 Female 2018 5,491
TX_NEW By Age/Sex: 25-49 Male 2018 2,562
TX_NEW By Age/Sex: 50+ Female 2018 230
TX_NEW By Age/Sex: 50+ Male 2018 368
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 10,587
TX_NEW Sum of Age/Sex disaggregates 2018 10,385
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 41,631
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 37,288
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 721
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 687
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 24,125
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 11,755
TX_PVLS Numerator: Indication: Routine 2018 37,288
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 972
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 878
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 26,737
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 13,044
TX_PVLS_den Denominator: Indication: Routine 2018 41,631
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 127
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 118
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 6,359
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 2,922
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 9,526
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 10,587
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 143
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 133
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 7,060
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3,251
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 41,631
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 630
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 21
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 20
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 275
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 314
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 895
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 857
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 26,808
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 13,071
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 6,464
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 415
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 1,251
TX_TB_den Denominator: By Screen Result: Negative 2018 33,304
TX_TB_den Denominator: By Screen Result: Positive 2018 8,326
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 7,911
VMMC_CIRC By Age: 10-14 2018 2,490
VMMC_CIRC By Age: 15-19 2018 622
VMMC_CIRC By Age: 20-24 2018 622
VMMC_CIRC By Age: 25-29 2018 1,245
VMMC_CIRC By Age: 30-49 2018 1,183
VMMC_CIRC By Age: 50+ 2018 62
VMMC_CIRC By circumcision technique: Surgical VMMC 2018 6,224
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 6,224
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2018 6,224
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2018 3,796
Cross Cutting Budget Categories and Known Amounts Total: $223,728
Gender: Gender Based Violence (GBV) $73,728
GBV Prevention
Implementation
Monitoring and Evaluation
Post GBV Care
Implementation
Monitoring and Evaluation
Water $150,000